公开(公告)号：US08367864B2

公开(公告)日：2013-02-05

申请号：US12694828

申请日：2010-01-27

申请人： Alex Moffett ,  Parag Shah

发明人： Alex Moffett ,  Parag Shah

IPC分类号： C07C51/09

CPC分类号： C07C59/245 ,  A61K31/19

摘要： The present invention relates to soluble dimeric double metal salt compositions of (−)-hydroxycitric acid (“HCA”), as well as methods for making and using the same. The invention provides dimeric double metal salts of group IA and IIA of HCA (hereinafter, “DDM-HCAs”). The present invention provides methods to make DDM-HCAs of the invention which can be employed to alter the polar/ionic qualities of HCA salts and derivatives to improve solubility of HCA compositions. DDM-HCAs of the invention are soluble HCA-containing compositions useful as dietary supplements and suitable for manipulations under those conditions necessary for tabletting, encapsulation, and the production of dry powders, particularly for use as a beverage premix. Methods of use of the composition include treatment for suppression of appetite, for weight loss, for an increase in the rate of fat metabolism, for reduction in blood lipids and postprandial lipemia, and to increase the plasma level of (−)-hydroxycitric acid.

摘要翻译： 本发明涉及（ - ） - 羟基柠檬酸（HCA）的可溶性二聚双金属盐组合物及其制备和使用方法。 本发明提供了HCA（以下称为DDM-HCAs）的IA和IIA族二聚双金属盐。 本发明提供制备本发明的DDM-HCAs的方法，其可用于改变HCA盐和衍生物的极性/离子质量以改善HCA组合物的溶解性。 本发明的DDM-HCAs是可溶于含HCA的组合物，其可用作膳食补充剂并且适于在用于压片，包封和干燥粉末生产所需的那些条件下操作，特别是用作饮料预混物。 组合物的使用方法包括抑制食欲，体重减轻，脂肪代谢速率增加，血脂降低和餐后脂血症以及增加（ - ） - 羟基柠檬酸的血浆水平的治疗。

公开(公告)号：US20080124416A1

公开(公告)日：2008-05-29

申请号：US11945888

申请日：2007-11-27

申请人： Alex Moffett

发明人： Alex Moffett

IPC分类号： A61K36/815 ,  A61K31/715 ,  A61P17/00 ,  A61P3/10 ,  A61P9/00

CPC分类号： A61K36/815 ,  A61K31/015 ,  A61K31/715

摘要： The present invention relates to herbal-derived compositions comprising extracts of polysaccharides and carotenoids from Goji species for management of ocular disorders, diabetes, bone metabolism, arthritis, muscle loss, cardiovascular disorders, immunological disorders, fatigue, body weight, sexual disorders, aging disorders, dermatological disorders and neurological disorders. Further provided are methods for making the compositions, and methods for treating subjects with various adverse health conditions with therapeutically or health-promotionally effective amounts of the compositions.

摘要翻译： 本发明涉及包含来自Goji物种的多糖和类胡萝卜素提取物的草药衍生组合物，用于治疗眼部疾病，糖尿病，骨代谢，关节炎，肌肉损失，心血管疾病，免疫学障碍，疲劳，体重，性障碍，衰老障碍 ，皮肤病和神经障碍。 还提供了制备组合物的方法，以及用于治疗或健康促进有效量的组合物治疗具有不同健康状况的受试者的方法。

公开(公告)号：US20060105069A1

公开(公告)日：2006-05-18

申请号：US11281302

申请日：2005-11-16

申请人： Alex Moffett ,  Parag Shah

发明人： Alex Moffett ,  Parag Shah

IPC分类号： A61K36/185

CPC分类号： A61K36/38 ,  A23L33/105 ,  A61K8/97 ,  A61K31/352 ,  A61K31/7024 ,  A61Q5/006 ,  A61Q19/00 ,  A61Q19/08 ,  A61K2300/00

摘要： The present invention relates to pharmaceutical, therapeutic, nutritional, cosmetic, and dermatological compositions derived from the preicarp (rind) of the Garcinia mangostana L plant and the novel extraction processes used to produce those compositions. Specifically, the present invention relates, in part, to an approximately 0.01% to about 80% mixture of a xanthone-rich mangosteen pericarp (rind) extract in novel combinations for pharmaceutical, cosmetic, therapeutic or dermatological compositions that yield surprising health benefits. Additionally, the present invention relates, in part, to novel extraction processes that result in the production of the novel compositions of the invention.

公开(公告)号：US20080145408A1

公开(公告)日：2008-06-19

申请号：US11611817

申请日：2006-12-15

申请人： Alex Moffett ,  Parag Shah

发明人： Alex Moffett ,  Parag Shah

IPC分类号： A61K31/19 ,  A61K9/14 ,  A61K9/48

CPC分类号： C07C59/245 ,  A61K31/19

摘要： The present invention relates to soluble dimeric double metal salt compositions of (−)-hydroxycitric acid (“HCA”), as well as methods for making and using the same. The invention provides dimeric double metal salts of group IA and IIA of HCA (hereinafter, “DDM-HCAs”). The present invention provides methods to make DDM-HCAs of the invention which can be employed to alter the polar/ionic qualities of HCA salts and derivatives to improve solubility of HCA compositions. DDM-HCAs of the invention are soluble HCA-containing compositions useful as dietary supplements and suitable for manipulations under those conditions necessary for tabletting, encapsulation, and the production of dry powders, particularly for use as a beverage premix. Methods of use of the composition include treatment for suppression of appetite, for weight loss, for an increase in the rate of fat metabolism, for reduction in blood lipids and postprandial lipemia, and to increase the plasma level of (−)-hydroxycitric acid.

摘要翻译： 本发明涉及（ - ） - 羟基柠檬酸（“HCA”）的可溶性二聚双金属盐组合物，以及其制备和使用方法。 本发明提供HCA的IA和IIA的二聚双金属盐（以下称为“DDM-HCAs”）。 本发明提供制备本发明的DDM-HCAs的方法，其可用于改变HCA盐和衍生物的极性/离子质量以改善HCA组合物的溶解性。 本发明的DDM-HCAs是可溶于含HCA的组合物，其可用作膳食补充剂并且适于在用于压片，包封和干燥粉末生产所需的那些条件下操作，特别是用作饮料预混物。 组合物的使用方法包括抑制食欲，体重减轻，脂肪代谢速率增加，血脂降低和餐后脂血症以及增加（ - ） - 羟基柠檬酸的血浆水平的治疗。

公开(公告)号：US20060198907A1

公开(公告)日：2006-09-07

申请号：US11317939

申请日：2005-12-22

申请人： Alex Moffett ,  Parag Shah

发明人： Alex Moffett ,  Parag Shah

IPC分类号： A61K36/18

CPC分类号： A61K31/7016 ,  A61K31/19 ,  A61K31/70 ,  A61K36/185 ,  A61K36/61 ,  A61K2300/00

摘要： The present invention relates to pharmaceutical, therapeutic, and dietary compositions derived from leaf of the Lagerstroemia speciosa L. plant and the novel extraction processes used to produce these controlled blends of varying composition with respect to corosolic acid, gallotannins, ellagitannins, and valoneic acid dilactone. Embodiments of the invention include an approximately 15.5% to about 98.5% mixture of a corosolic acid rich banaba leaf extract in a tannic acid enriched base for novel combinations for pharmaceutical, therapeutic and/or dietary compositions that yield healthful benefits. Some embodiments of the invention do not include corosolic acid, or include it at a low concentration in combination particularly enriched in other compounds. Such extract compositions that do not contain corosolic acid, are the product of extraction process that yield controllably increased ratios of gallotannins, ellagitannins, and valoneic acid dilactone. Such compositions, both those containing corosolic acid and those lacking corosolic acid are efficacious in effecting control of blood glucose levels, and can be further enhanced in their efficacy by post production and formulation strategies that utilize nanotechnological approaches, targeted deliver enteric coatings, and specialized microenacapsulations. With respect to the individual compounds of these extract compositions, such compounds show combined effects that are both additive and synergistic regarding improved glucose cellular uptake, reduction in blood glucose, insulin efficiency and the simultaneous reduction in assimilation of sugars and starches, and weight loss. Further, additive and synergistic effects are a potential benefit when these compositions are combined with other second therapeutic agents.

摘要翻译： 本发明涉及衍生自紫薇属植物叶的叶片的药物，治疗和饮食组合物，以及用于制备相对于科罗索酸，gal单宁，鞣花素和缬氨酸二酮的不同组成的这些受控共混物的新提取方法 。 本发明的实施方案包括产生健康益处的用于药物，治疗和/或膳食组合物的新型组合的富含丹宁酸的碱的富含科罗多糖的巴拉巴叶提取物的约15.5％至约98.5％的混合物。 本发明的一些实施方案不包括科罗索酸，或将其以低浓度组合，特别富集其它化合物。 不含科罗索酸的这种提取物组合物是提取方法的产物，其产生可控增加的gal单宁，鞣花素和缬氨酸二酮的比例。 这些组合物，包含科罗索酸和缺乏科罗索酸的组合物在实现血糖水平的控制方面是有效的，并且可以通过后期制备和使用纳米技术方法，靶向递送肠溶衣和专门的微囊封装的制剂策略进一步提高其功效 。 关于这些提取物组合物的各种化合物，这些化合物显示出对于改善的葡萄糖细胞摄取，降低血糖，胰岛素效率以及同时减少糖和淀粉的同化以及减肥的综合作用。 此外，当这些组合物与其它第二治疗剂组合时，添加剂和协同效应是潜在的益处。

公开(公告)号：US20110003896A1

公开(公告)日：2011-01-06

申请号：US12694828

申请日：2010-01-27

申请人： Alex Moffett ,  Parag Shah

发明人： Alex Moffett ,  Parag Shah

IPC分类号： A61K31/194 ,  C07C59/245 ,  C07C51/42 ,  A61P3/04 ,  A61P3/00 ,  A61P3/06

CPC分类号： C07C59/245 ,  A61K31/19

摘要： The present invention relates to soluble dimeric double metal salt compositions of (−)-hydroxycitric acid (“HCA”), as well as methods for making and using the same. The invention provides dimeric double metal salts of group IA and IIA of HCA (hereinafter, “DDM-HCAs”). The present invention provides methods to make DDM-HCAs of the invention which can be employed to alter the polar/ionic qualities of HCA salts and derivatives to improve solubility of HCA compositions. DDM-HCAs of the invention are soluble HCA-containing compositions useful as dietary supplements and suitable for manipulations under those conditions necessary for tabletting, encapsulation, and the production of dry powders, particularly for use as a beverage premix. Methods of use of the composition include treatment for suppression of appetite, for weight loss, for an increase in the rate of fat metabolism, for reduction in blood lipids and postprandial lipemia, and to increase the plasma level of (−)-hydroxycitric acid.

摘要翻译： 本发明涉及（ - ） - 羟基柠檬酸（“HCA”）的可溶性二聚双金属盐组合物，以及其制备和使用方法。 本发明提供HCA的IA和IIA的二聚双金属盐（以下称为“DDM-HCAs”）。 本发明提供制备本发明的DDM-HCAs的方法，其可用于改变HCA盐和衍生物的极性/离子质量以改善HCA组合物的溶解性。 本发明的DDM-HCAs是可溶于含HCA的组合物，其可用作膳食补充剂并且适于在用于压片，包封和干燥粉末生产所需的那些条件下操作，特别是用作饮料预混物。 组合物的使用方法包括抑制食欲，体重减轻，脂肪代谢速率增加，血脂降低和餐后脂血症以及增加（ - ） - 羟基柠檬酸的血浆水平的治疗。

公开(公告)号：US20060292255A1

公开(公告)日：2006-12-28

申请号：US11473486

申请日：2006-06-22

申请人： Alex Moffett ,  Parag Shah

发明人： Alex Moffett ,  Parag Shah

IPC分类号： A61K36/185

CPC分类号： A61K36/38 ,  A23L33/105 ,  A61K8/97 ,  A61K31/352 ,  A61K31/7024 ,  A61Q5/006 ,  A61Q19/00 ,  A61Q19/08 ,  A61K2300/00

摘要： The present invention relates to pharmaceutical, therapeutic, nutritional, cosmetic, and dermatological compositions derived from the preicarp (rind) of the Garcinia mangostana L plant and the novel extraction processes used to produce those compositions. Specifically, the present invention relates, in part, to an approximately 0.01% to about 80% mixture of a xanthone-rich mangosteen pericarp (rind) extract in novel combinations for pharmaceutical, cosmetic, therapeutic or dermatological compositions that yield surprising health benefits. Additionally, the present invention relates, in part, to novel extraction processes that result in the production of the novel compositions of the invention.

摘要翻译： 本发明涉及衍生自芒of藤的植物前体（皮）的药物，治疗，营养，化妆品和皮肤病学组合物，以及用于生产这些组合物的新的提取方法。 具体地，本发明部分地涉及产生令人惊讶的健康益处的药物，化妆品，治疗或皮肤病学组合物的新颖组合的约0.01％至约80％的富含呫吨酮的山竹果皮（皮）提取物的混合物。 另外，本发明部分涉及导致生产本发明的新型组合物的新的提取方法。